TECHNOLOGY
ABOUT US
CONTACT
OUR MISSION
The FrostBite endoscopic ultrasound (EUS) compatible cryocatheter powered by the PSN cryoengine represent a novel Cryoablation Technology Platform. Phase Therapeutics is focused on the commercialization of these minimally-invasive cryoablation devices to target pancreatic tissue via an endoscopic approach. Phase Therapeutics devices have the potential to revolutionize pancreatic cancer and GI tissue ablative therapy
FrostBite – Powered By PSN
EUS comPATIBILITY
+
POWERFUL CRYOGEN
+
PRECISE THERAPEUTIC DELIVERY
Revolutionizing
treatment
possibilities
PANCREATIC CANCER STATISTICS (USA DATA)
American Cancer Society, Cancer Facts & Figures 2022
4th
Leading Cause of Cancer Deaths in U.S.
11%
Relative 5 yr. Survival Rate
62,210
New Cases in 2022
49,830
Lives Lost in the U.S. in 2022 alone
Harnessing Technology Advancements to Address Unmet Clinical Needs
Combining the Work Capacity of Liquid Cryogens with the Speed and Control of Gas
TEAM
Bringing Phase Therapeutics’ innovative devices through regulatory approval into the market to impact patient lives is the focused goal of the Phase Therapeutics team.
Jeremy Starkweather
Managing Director
John Wynne
Director, BD
Jason Ylizarde
Director, Commercialization
John M. Baust, Ph.D
Founder and CTO
Kristi K. Snyder, Ph.D
Director, R&D
Christen Springs
Director, Operations
Building upon the need for new approaches to treat pancreatic cancer and the overall growing clinical acceptance of cryoablation, Phase Therapeutics believes that FrostBite and PSN are poised to be a leading technology in gastroenterology
IMPACTING PANCREATIC CANCER
Pancreatic cancer and cysts are often diagnosed by Gastroenterologists using an EUS approach. The ultrasound at the tip of the endoscope permits the physician to visualize pancreatic tissue from inside the stomach. Using the working channel of the EUS scope, Biopsy Needles can be guided to take samples of tissue by accessing the pancreas through the stomach wall. This minimally-invasive method is commonly used to diagnose patients. FrostBite would be the 1st EUS compatible cryoablation tool in Gastroenterologist’s hands to treat tumors and tissues they currently biopsy.
Therapeutic Tools Designed to work with Advanced Diagnostics
The Future is FrostBite.
opportunity
Phase Therapeutics is opening Investment Opportunities while engaging with Strategic Partners to advance the FrostBite and PSN platform technologies.
Contact us for more information.
Contact Us
We look forward to hearing from you
Phase Therapeutics cannot diagnose or treat patients. Please consult your physician.
Disclaimer: Phase Therapeutics’ technologies are currently Investigational Devices and are limited by Federal Law to Investigational Use Only.